Acacia Research Valuation Multiples

Acacia Research is valued at $413M as of October 2026, a 0.8x revenue multiple. In the last 12 months, Acacia Research revenue was $265M and Acacia Research EBITDA was $33M.

Acacia Research Overview

About Acacia Research

Acacia Research Corp is focused on acquiring and operating businesses across the industrial, energy, and technology sectors where it believes it can leverage its expertise, capital base, and deep industry relationships to drive value. The company has four reportable business segments: Intellectual Property Operations, Industrial Operations, Energy Operations and Manufacturing Operations. It derives revenue from Intellectual Property Operations segment. Geographically, it operates in Americas, Europe, Middle East and Africa, China, India, and Asia-Pacific, excluding China and India.


Founded

1993

HQ

United States

Employees

1.0K

Sectors

Financials (LTM)

Revenue: $265M
EBITDA: $33M

EV

$212M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Acacia Research Financials

Acacia Research reported last 12-month revenue of $265M and EBITDA of $33M.

In the same LTM period, Acacia Research generated $61M in gross profit, $33M in EBITDA, and had net loss of ($24M).

Revenue (LTM)


Acacia Research P&L

In the most recent fiscal year, Acacia Research reported revenue of $285M and EBITDA of $72M.

Acacia Research is profitable as of last fiscal year, with gross margin of 30%, EBITDA margin of 25%, and net margin of 8%.

See analyst estimates for Acacia Research
LTMLast FY202320242025202620272028
Revenue$265M$285M$125M$122M$285M
Gross Profit$61M$84M$72M$30M$84M
Gross Margin23%30%58%24%30%
EBITDA$33M$72M$70M($16M)$72M
EBITDA Margin13%25%56%(13%)25%
EBIT Margin(7%)2%17%(27%)2%
Net Profit($24M)$22M$67M($36M)$22M
Net Margin(9%)8%54%(29%)8%
Net Debt-($210M)---

Financial data powered by Morningstar, Inc.

Acacia Research Stock Performance

Acacia Research has current market cap of $413M, and enterprise value of $212M.

Market Cap Evolution


Acacia Research's stock price is $4.23.

Acacia Research share price decreased by 1.9% in the last 30 days, and increased by 21.9% in the last year.

Acacia Research has an EPS (earnings per share) of $0.22.

See more trading valuation data for Acacia Research
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$212M$413M-1.6%-1.9%-3.5%21.9%$0.22

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Acacia Research Valuation Multiples

Acacia Research trades at 0.8x EV/Revenue multiple, and 6.4x EV/EBITDA.

See NTM and 2027E valuation multiples for Acacia Research

EV / Revenue (LTM)


Acacia Research Financial Valuation Multiples

As of October 16, 2026, Acacia Research has market cap of $413M and EV of $212M.

Acacia Research has a P/E ratio of (17.1x).

LTMLast FY202320242025202620272028
EV/Revenue0.8x0.7x1.7x1.7x0.7x
EV/EBITDA6.4x2.9x3.0x(13.5x)2.9x
EV/EBIT(10.9x)33.2x10.1x(6.5x)33.2x
EV/Gross Profit3.5x2.5x2.9x7.2x2.5x
P/E(17.1x)19.0x6.2x(11.4x)19.0x
EV/FCF-3.6x(7.4x)(1.9x)3.6x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Acacia Research Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Acacia Research Margins & Growth Rates

Acacia Research decreased revenue by 9% and EBITDA by 70% in the last fiscal year.

In the most recent fiscal year, Acacia Research reported gross margin of 30%, EBITDA margin of 25%, and net margin of 8%.

See estimated margins and future growth rates for Acacia Research

Acacia Research Margins

Last FY202420252026202720282029
Gross Margin30%24%30%21%
EBITDA Margin25%(13%)25%8%
EBIT Margin2%(27%)2%(10%)
Net Margin8%(29%)8%(14%)
FCF Margin21%(92%)21%-

Acacia Research Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth(9%)(2%)133%(9%)
Gross Profit Growth(35%)(59%)185%(35%)
EBITDA Growth(70%)(123%)(558%)(70%)
EBIT Growth(512%)(257%)(119%)(512%)
Net Profit Growth(267%)(154%)(160%)(267%)
FCF Growth-292%(152%)-

Data powered by FactSet, Inc. and Morningstar, Inc.

Acacia Research Operational KPIs

Acacia Research's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.

Acacia Research's Rule of 40 is (1%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Acacia Research's Rule of X is (14%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Acacia Research
LTMLast FY202320242025202620272028
Rule of 40(7%)(1%)---
Bessemer Rule of X(37%)(14%)---
Revenue per Employee-$0.3M---
Opex per Employee-$0.1M---
S&M Expenses to Revenue-5%6%6%5%
G&A Expenses to Revenue26%23%36%45%23%
R&D Expenses to Revenue--1%--
Opex to Revenue-27%41%51%27%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Acacia Research Competitors

Acacia Research competitors include Chrysalis Investments, International Biotechnology Trust, Republic Digital Acq, Kinea Unique Hy Cdi FII, MCI Capital, Kinea Securities FII, Qalaa Holdings, Pembroke VCT, Deutsche Beteiligungs and Albion Tech & Gen VCT.

Most Acacia Research public comparables operate across PE & VC.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Chrysalis Investments$167M-2.4x45.7x--
International Biotechnology Trust($237K)-(1951.2x)---
Republic Digital Acq------
Kinea Unique Hy Cdi FII$74M-6.0x---
MCI Capital$28M$21M16.1x-20.6x-
Kinea Securities FII$55M$45M6.2x-7.6x-
Qalaa Holdings$2.5B$430M1.2x-6.9x-
Pembroke VCT$16M-21.0x---

This data is available for Pro users. Sign up to see all Acacia Research competitors and their valuation data.

Start Free Trial

Acquisitions by Acacia Research

Acacia Research has acquired 3 companies to date.

Last acquisition by Acacia Research was on October 21st 2024. Acacia Research acquired Deflecto for $104M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Acacia Research

Deflecto
Benchmark Energy
Printronix
Description
Deflecto is a manufacturer of plastic products serving office, healthcare, and automotive markets. The company produces chair mats, floor protection, literature holders, and sign holders from recycled materials in facilities across the United States. Deflecto supplies major retailers like Staples, Office Depot, and Walmart with customizable desk accessories and cable management solutions. In the bicycle sector, it offers reflective tapes and lights for visibility enhancement. Indianapolis-headquartered since 1946, Deflecto maintains a global distribution network and emphasizes durable, eco-friendly polymers in its product lines.
Benchmark Energy is an independent exploration and production company headquartered in Houston, Texas, that develops conventional and unconventional oil and gas assets primarily in the Eagle Ford Shale and Permian Basin. The firm operates a portfolio of producing wells and undeveloped acreage across South Texas, emphasizing efficient drilling and completion techniques to maximize resource recovery. Benchmark Energy partners with midstream providers for transportation and processing, ensuring reliable market access for its crude oil and natural gas output. Established in 2014, the company maintains a focus on low-cost operations in prolific basins to deliver consistent production volumes.
Printronix is an Irvine, California-based provider of industrial printers and label solutions for enterprise environments such as warehouses, distribution centers, and manufacturing facilities. It offers thermal, inkjet, and laser printers integrated with network management software for high-volume printing in supply chain operations. Established in 1974, Printronix serves global markets with durable, high-performance printing systems.
HQ CountryUnited StatesUnited StatesUnited States
HQ City
Indianapolis, IN
Amarillo, TX
Los Angeles, CA
Deal Date21 Oct 202413 Nov 202311 Oct 2021
Valuation$104Mundisclosed$33M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Acacia Research acquisitions and their M&A valuation multiples.

Start Free Trial

Investments by Acacia Research

Acacia Research has invested in 7 companies to date.

Latest investment by Acacia Research was on June 5th 2020. Acacia Research invested in NovaBiotics in their Secondary round.

See VC round multiples

Latest Investments by Acacia Research

NovaBiotics
Immunocore Holdings
Viamet Pharmaceuticals
AMO Pharma
Description
NovaBiotics is an Aberdeen-headquartered clinical-stage biotechnology company developing anti-infectives for unmet medical needs. Its pipeline features Novexatin for onychomycosis in Phase IIb trials partnered with Taro Pharmaceuticals and Lynovex as an antibacterial-mucolytic for respiratory infections. NovaBiotics leverages proprietary peptide platforms to combat drug-resistant pathogens.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
Viamet Pharmaceuticals is a Durham-based biopharmaceutical firm developing metalloenzyme inhibitors using Metallophile technology. This platform optimizes metal-binding warheads to create superior analogs of approved drugs targeting fungal infections and oncology. Key programs include VT-1161 for onychomycosis, advanced to Phase 2 trials, and VT-1598 for cryptococcosis. Acquired by Recursion Pharmaceuticals in 2021, Viamet's portfolio advances treatments for resistant pathogens through structure-based design.
AMO Pharma is a biopharmaceutical company targeting rare muscular and central nervous system disorders with two clinical-stage assets. London-headquartered, the firm pursues acquisitions of development-stage products in neurology. Founded in 2010, AMO Pharma advances therapies like amlopidine for dystrophinopathies and conducts trials in the United States and Europe.
HQ CountryUnited KingdomUnited StatesUnited StatesUnited Kingdom
HQ City
Aberdeen
Aberdeen
Raleigh, NC
Wonersh
Deal Date5 Jun 20205 Jun 20205 Jun 20205 Jun 2020
RoundSecondarySecondarySecondarySecondary
Raisedundisclosedundisclosedundisclosedundisclosed
InvestorsAcacia ResearchAcacia ResearchAcacia ResearchAcacia Research
Valuationundisclosedundisclosedundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Acacia Research investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Acacia Research

When was Acacia Research founded?Acacia Research was founded in 1993.
Where is Acacia Research headquartered?Acacia Research is headquartered in United States.
How many employees does Acacia Research have?As of today, Acacia Research has over 1K employees.
Who is the CEO of Acacia Research?Acacia Research's CEO is Martin D. McNulty.
Is Acacia Research publicly listed?Yes, Acacia Research is a public company listed on Nasdaq.
What is the stock symbol of Acacia Research?Acacia Research trades under ACTG ticker.
When did Acacia Research go public?Acacia Research went public in 2002.
Who are competitors of Acacia Research?Acacia Research main competitors include Chrysalis Investments, International Biotechnology Trust, Republic Digital Acq, Kinea Unique Hy Cdi FII, MCI Capital, Kinea Securities FII, Qalaa Holdings, Pembroke VCT, Deutsche Beteiligungs, Albion Tech & Gen VCT.
What is the current market cap of Acacia Research?Acacia Research's current market cap is $413M.
What is the current revenue of Acacia Research?Acacia Research's last 12 months revenue is $265M.
What is the current revenue growth of Acacia Research?Acacia Research revenue growth (NTM/LTM) is (20%).
What is the current EV/Revenue multiple of Acacia Research?Current revenue multiple of Acacia Research is 0.8x.
What is the current EBITDA of Acacia Research?Acacia Research's last 12 months EBITDA is $33M.
What is Acacia Research's EBITDA margin?Acacia Research's last 12 months EBITDA margin is 13%.
What is the current EV/EBITDA multiple of Acacia Research?Current EBITDA multiple of Acacia Research is 6.4x.
How many companies Acacia Research has acquired to date?As of October 2026, Acacia Research has acquired 3 companies.
What was the largest acquisition by Acacia Research?$104M acquisition of Deflecto on 21st October 2024 was the largest M&A Acacia Research has done to date.
What companies Acacia Research acquired?Acacia Research acquired Deflecto, Printronix, and Benchmark Energy.
In how many companies Acacia Research has invested to date?As of October 2026, Acacia Research has invested in 7 companies.
What was the last Acacia Research investment?On 5th June 2020 Acacia Research invested in NovaBiotics, participating in a Secondary round.
In what companies Acacia Research invested in?Acacia Research invested in Veritone, Miso Robotics, Bitzumi, NovaBiotics, Immunocore Holdings, Viamet Pharmaceuticals, and AMO Pharma.

See public comps similar to Acacia Research

Lists including Acacia Research

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial